Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Non Randomized, Open Label, Phase II Trial to Assess the Efficacy and Safety of Bevacizumab Plus Capecitabine and Oxaliplatin, as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polichemotherapy Treatment.

Next Previous
Search
Trial Profile

A Non Randomized, Open Label, Phase II Trial to Assess the Efficacy and Safety of Bevacizumab Plus Capecitabine and Oxaliplatin, as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polichemotherapy Treatment.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms BECOX

    • Most Recent Events

    • 19 Jun 2014 Status changed from active, no longer recruiting to completed according to results published in the British Journal of Cancer.
    • 29 Jan 2014 Planned End Date changed from 1 Dec 2012 to 1 Mar 2014 as per ClinicalTrials.gov record.
    • 20 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top